ATE494906T1 - Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna - Google Patents

Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna

Info

Publication number
ATE494906T1
ATE494906T1 AT06831855T AT06831855T ATE494906T1 AT E494906 T1 ATE494906 T1 AT E494906T1 AT 06831855 T AT06831855 T AT 06831855T AT 06831855 T AT06831855 T AT 06831855T AT E494906 T1 ATE494906 T1 AT E494906T1
Authority
AT
Austria
Prior art keywords
cell
dna
cell culture
low amounts
residual
Prior art date
Application number
AT06831855T
Other languages
German (de)
English (en)
Inventor
Jens-Peter Gregersen
Holger Kost
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37969762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE494906(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE494906T1 publication Critical patent/ATE494906T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06831855T 2005-11-01 2006-11-01 Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna ATE494906T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73278605P 2005-11-01 2005-11-01
PCT/IB2006/003880 WO2007052163A2 (en) 2005-11-01 2006-11-01 Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment

Publications (1)

Publication Number Publication Date
ATE494906T1 true ATE494906T1 (de) 2011-01-15

Family

ID=37969762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06831855T ATE494906T1 (de) 2005-11-01 2006-11-01 Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna

Country Status (19)

Country Link
US (2) US10655108B2 (cg-RX-API-DMAC7.html)
EP (3) EP2301572B1 (cg-RX-API-DMAC7.html)
JP (5) JP5602366B2 (cg-RX-API-DMAC7.html)
KR (1) KR20080081254A (cg-RX-API-DMAC7.html)
CN (2) CN104474543A (cg-RX-API-DMAC7.html)
AT (1) ATE494906T1 (cg-RX-API-DMAC7.html)
AU (2) AU2006310171B2 (cg-RX-API-DMAC7.html)
CA (1) CA2627971A1 (cg-RX-API-DMAC7.html)
CY (1) CY1111378T1 (cg-RX-API-DMAC7.html)
DE (1) DE602006019629D1 (cg-RX-API-DMAC7.html)
DK (1) DK1951296T4 (cg-RX-API-DMAC7.html)
EA (1) EA014062B1 (cg-RX-API-DMAC7.html)
ES (2) ES2359214T5 (cg-RX-API-DMAC7.html)
HK (1) HK1207828A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ567817A (cg-RX-API-DMAC7.html)
PL (2) PL1951296T5 (cg-RX-API-DMAC7.html)
PT (1) PT2301572E (cg-RX-API-DMAC7.html)
SI (1) SI1951296T2 (cg-RX-API-DMAC7.html)
WO (1) WO2007052163A2 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104474543A (zh) * 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
CA2640248A1 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Influenza vaccines containing hemagglutinin and matrix proteins
EP2497495B3 (en) 2006-09-11 2021-02-17 Seqirus UK Limited Making influenza virus vaccines without using eggs
DK2185191T3 (da) * 2007-06-27 2012-12-03 Novartis Ag Influenzavacciner med lavt indhold af tilsætningsstoffer
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
AU2009227674C1 (en) 2008-03-18 2015-01-29 Seqirus UK Limited Improvements in preparation of influenza virus vaccine antigens
EP2361304A2 (en) 2008-11-05 2011-08-31 GlaxoSmithKline Biologicals S.A. Novel method
CN102548577A (zh) 2009-04-27 2012-07-04 诺华有限公司 用于抵抗流感的佐剂疫苗
EP2401384B1 (en) 2009-05-21 2012-10-03 Novartis AG Reverse genetics using non-endogenous pol i promoters
CN104862335A (zh) 2009-07-31 2015-08-26 诺华股份有限公司 反向遗传系统
IN2012DN03418A (cg-RX-API-DMAC7.html) 2009-10-09 2015-10-23 Childrens Medical Center
WO2011048560A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
BR112012027643A2 (pt) 2010-05-03 2016-08-16 Glaxosmithkline Biolog Sa métodos para a inativação de um orthomixovírus, para a preparação de uma vacina, e , composição imunogênica
MX343948B (es) 2010-05-06 2016-11-30 Novartis Ag * Compuestos de peroxido organico para inactivacion de microorganismos.
AU2011254204B2 (en) 2010-05-21 2015-08-20 Seqirus UK Limited Influenza virus reassortment method
CN102939104A (zh) 2010-06-01 2013-02-20 诺华有限公司 用冻干浓缩疫苗抗原
WO2011151723A2 (en) 2010-06-01 2011-12-08 Novartis Ag Concentration of vaccine antigens without lyophilization
SG188947A1 (en) 2010-08-12 2013-06-28 Yisheng Biopharma Holdings Ltd Method for reducing dna impurities in viral compositions
WO2012023044A1 (en) 2010-08-20 2012-02-23 Novartis Ag Soluble needle arrays for delivery of influenza vaccines
CA2828192A1 (en) 2011-02-25 2012-08-30 Novartis Ag Exogenous internal positive control
EP3290050B1 (en) 2011-11-03 2019-01-02 Sentinext Therapeutics SDN BHD Vaccines directed against human enteroviruses
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
WO2013087945A2 (en) 2012-03-02 2013-06-20 Novartis Ag Influenza virus reassortment
WO2013131898A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Improved vaccination against influenza
CA2875752A1 (en) 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
US9708585B2 (en) 2012-12-03 2017-07-18 Seqirus UK Limited Influenza virus reassortment
EP2968512A2 (en) 2013-03-13 2016-01-20 Novartis AG Influenza b virus reassortment
US20140335116A1 (en) 2013-05-10 2014-11-13 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
AU2014276418A1 (en) 2013-06-06 2016-01-21 Novartis Ag Influenza virus reassortment
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
CN104513317B (zh) * 2013-09-30 2018-12-14 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
US20160287693A1 (en) 2013-11-15 2016-10-06 Novartis Ag Removal of residual cell culture impurities
JP6774149B2 (ja) * 2014-05-28 2020-10-21 ナショナル ヘルス リサーチ インスティテューツＮａｔｉｏｎａｌ Ｈｅａｌｔｈ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅｓ エンテロウイルス感染に対する免疫原としてのウイルス粒子およびその生産
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
WO2017005880A1 (en) 2015-07-07 2017-01-12 Seqirus UK Limited Influenza potency assays
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
AU2018357917B2 (en) 2017-10-30 2024-08-01 Takeda Pharmaceutical Company Limited Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
KR20220098370A (ko) * 2019-11-07 2022-07-12 세퀴러스 유케이 리미티드 감소된 입자 크기를 가지는 바이러스 백신을 제조하기 위한 조성물 및 방법
US20230000971A1 (en) 2019-11-18 2023-01-05 Seqirus Pty Ltd. Method for producing reassortant influenza viruses
EP4316515A4 (en) * 2021-03-30 2024-09-25 Denka Company Limited Influenza vaccine
CN115354071A (zh) * 2022-08-10 2022-11-18 上海药明生基医药科技有限公司 一种检测重组腺相关病毒宿主细胞dna残留的方法
CN116407624B (zh) * 2023-04-14 2024-04-09 吉林省农业科学院(中国农业科技东北创新中心) 一种鸡传染性支气管炎细菌样颗粒疫苗的制备方法和应用
TW202516000A (zh) * 2023-07-25 2025-04-16 日商Ｋｍ生物醫藥股份有限公司 利用雞蛋培養法進行的去活化流感疫苗的製備方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
CH589453A5 (cg-RX-API-DMAC7.html) * 1974-01-14 1977-07-15 Sandoz Ag
US4140762A (en) * 1974-01-14 1979-02-20 Sandoz Ltd. Influenza sub-unit vaccine
EP0251575B2 (en) 1986-06-17 2002-11-13 Chiron Corporation Hepatitis delta diagnostics and vaccines, their preparation and use
GB8703696D0 (en) * 1987-02-18 1987-03-25 Oxford J S Influenza vaccine
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
JP2941859B2 (ja) 1989-09-20 1999-08-30 国立予防衛生研究所 Ｈａ蛋白の製造法
US5010112A (en) * 1989-12-01 1991-04-23 Massachusetts Institute Of Technology Method and apparatus for improving the insulating properties of closed cell foam
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
WO1999062546A1 (en) * 1998-06-01 1999-12-09 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants
JP2000230931A (ja) 1998-12-07 2000-08-22 Katakura Industries Co Ltd 家畜インフルエンザウイルスに対する抗体の検出方法およびこれに用いるキット
WO2000062800A2 (en) * 1999-04-19 2000-10-26 Smithkline Beecham Biologicals Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
IL148673A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Intranasal influenza virus vaccine
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
AU3241501A (en) 1999-12-08 2001-06-18 Crucell Holland B.V. Method of administering adenovirus
US6825036B2 (en) 2000-03-03 2004-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
EP2281573A3 (en) * 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
DE10293048T1 (de) 2001-04-27 2003-07-31 Glaxosmithkline Biolog Sa Neuer Impfstoff
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
DE10144903A1 (de) 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
ES2526191T3 (es) * 2002-04-26 2015-01-08 Medimmune, Llc Método para producir virus influenza B infeccioso en cultivo celular
WO2004056979A2 (en) 2002-12-20 2004-07-08 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
ES2529736T3 (es) * 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
EA012965B1 (ru) 2003-05-28 2010-02-26 Висконсин Эламни Рисёч Фаундэйшн Композиция для получения реассортантного рекомбинантного вируса гриппа, способ получения указанного вируса и реассортантный рекомбинантный вирус гриппа
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
AU2005245943A1 (en) 2004-05-20 2005-12-01 Id Biomedical Corporation Process for the production of an influenza vaccine
ES2386272T3 (es) 2004-09-09 2012-08-16 Novartis Vaccines And Diagnostics Gmbh Reducción de riesgos iatrogénicos potenciales asociados a las vacunas antigripales
JP4031478B2 (ja) 2004-12-13 2008-01-09 プロテイン サイエンシーズ インフルエンザ血球凝集素多価ワクチンの製造方法
EP2368975B1 (en) 2004-12-23 2014-09-17 MedImmune, LLC Non-tumorigenic MDCK cell line for propagating viruses
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
CN104474543A (zh) * 2005-11-01 2015-04-01 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
CN103361319A (zh) * 2006-09-15 2013-10-23 米迪缪尼有限公司 支持病毒生长到高效价的mdck细胞系和采用该细胞系的生物反应器方法

Also Published As

Publication number Publication date
ES2525518T3 (es) 2014-12-26
EP1951296B2 (en) 2014-07-23
JP5602366B2 (ja) 2014-10-08
SI1951296T1 (sl) 2011-04-29
EP1951296A2 (en) 2008-08-06
JP2009513694A (ja) 2009-04-02
US20090304729A1 (en) 2009-12-10
JP6639077B2 (ja) 2020-02-05
ES2359214T3 (es) 2011-05-19
US10655108B2 (en) 2020-05-19
HK1129837A1 (en) 2009-12-11
PL1951296T3 (pl) 2011-09-30
JP2011256209A (ja) 2011-12-22
CN104474543A (zh) 2015-04-01
PT2301572E (pt) 2014-12-22
US11466257B2 (en) 2022-10-11
JP7049761B2 (ja) 2022-04-07
AU2006310171A1 (en) 2007-05-10
KR20080081254A (ko) 2008-09-09
AU2011201968B2 (en) 2014-08-28
CN101365480A (zh) 2009-02-11
BRPI0618094A8 (pt) 2017-08-22
DK1951296T3 (da) 2011-03-28
JP2020023557A (ja) 2020-02-13
PL2301572T3 (pl) 2015-02-27
EP1951296B1 (en) 2011-01-12
EA014062B1 (ru) 2010-08-30
CY1111378T1 (el) 2015-08-05
EA200801221A1 (ru) 2008-10-30
WO2007052163A2 (en) 2007-05-10
DE602006019629D1 (de) 2011-02-24
JP2016185988A (ja) 2016-10-27
EP2301572B1 (en) 2014-09-10
AU2006310171B2 (en) 2011-02-17
WO2007052163A3 (en) 2007-09-07
HK1207828A1 (en) 2016-02-12
US20200377864A1 (en) 2020-12-03
AU2011201968A1 (en) 2011-05-19
EP2301572A1 (en) 2011-03-30
JP2014198726A (ja) 2014-10-23
CN101365480B (zh) 2014-11-05
SI1951296T2 (sl) 2014-09-30
NZ567817A (en) 2012-01-12
ES2359214T5 (es) 2014-10-08
EP2842572A1 (en) 2015-03-04
PL1951296T5 (pl) 2015-06-30
DK1951296T4 (da) 2014-09-01
BRPI0618094A2 (pt) 2011-08-16
CA2627971A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
ATE494906T1 (de) Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
MX2012001592A (es) Composicion para el tratamiento de la infección del virus de la hepatitis b.
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
CY1114298T1 (el) Διαμορφωτικως περιορισμενα διφαινυλ παραγωγα για χρηση ως αναστολεις ιου ηπατιτιδας c
BRPI0922867B8 (pt) glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada
EA200870304A1 (ru) Псевдоинфекционный флавивирус и его применение
MX362981B (es) Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido.
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
MX346862B (es) Secuencias consenso de envoltura de vih y método para usar las mismas.
BRPI0920240B8 (pt) composição adjuvante
BR112013002729A2 (pt) inibidores de vírus de hepatite c
WO2010019262A3 (en) Polyvalent vaccine
BR112013020042A2 (pt) inibidores de vírus da hepatite c
EP4043031A3 (en) Zika viral antigen constructs
UA108902C2 (uk) Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
CL2011001343A1 (es) Pestivirus quimerico que comprende un virus de la diarrea viral bovina (bvdv) que expresa proteina erns de antilope; celula huesped que lo comprende; acido nucleico que lo codifica; composicion inmunogenica que comprende el pestivirus; vacuna marcadora que comprende el bvdv quimerico.
WO2013001285A3 (en) Fmdv vp1 peptides
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
MA37749B1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1951296

Country of ref document: EP